首页> 外文期刊>Antimicrobial agents and chemotherapy. >Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears.
【24h】

Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears.

机译:用于检测痰涂片中耐利福平的结核分枝杆菌的等位基因特异性rpoB PCR分析。

获取原文
获取原文并翻译 | 示例
           

摘要

We describe an allele-specific PCR assay to detect mutations in three codons of the rpoB gene (516, 526, and 531) in Mycobacterium tuberculosis strains; mutations in these codons are reported to account for majority of M. tuberculosis clinical isolates resistant to rifampin (RIF), a marker of multidrug-resistant tuberculosis (MDR-TB). Three different allele-specific PCRs are carried out either directly with purified DNA (single-step multiplex allele-specific PCR), or with preamplified rpoB fragment (nested allele-specific PCR [NAS-PCR]). The method was optimized and validated following analysis of 36 strains with known rpoB sequence. A retrospective analysis of the 287 DNA preparations from epidemiologically unlinked RIF-resistant clinical strains from Russia, collected from 1996 to 2002, revealed that 247 (86.1%) of them harbored a mutation in one of the targeted rpoB codons. A prospective study of microscopy-positive consecutive sputum samples from new and chronic TB patients validated the method fordirect analysis of DNA extracted from sputum smears. The potential of the NAS-PCR to control for false-negative results due to lack of amplification was proven especially useful in the study of these samples. The developed rpoB-PCR assay can be used in clinical laboratories to detect RIF-resistant and hence MDR M. tuberculosis in the regions with high burdens of the MDR-TB.
机译:我们描述了一种等位基因特异性PCR检测方法,以检测结核分枝杆菌菌株中rpoB基因的三个密码子(516、526和531)中的突变;据报道,这些密码子中的突变是结核分枝杆菌临床分离株的主要成分,对利福平(RIF)(一种耐多药结核病(MDR-TB)的标志物)具有耐药性。可以直接使用纯化的DNA(单步多重等位基因特异性PCR)或使用预先扩增的rpoB片段(嵌套等位基因特异性PCR [NAS-PCR])进行三种不同的等位基因特异性PCR。在分析了36个具有已知rpoB序列的菌株后,对该方法进行了优化和验证。回顾性分析从1996年到2002年收集的来自俄罗斯的流行病学上不相关的RIF耐药临床菌株的287个DNA制剂,其中247个(86.1%)在一个目标rpoB密码子中具有突变。对来自新的和慢性结核病患者的显微镜阳性连续痰标本进行的前瞻性研究证实了直接分析从痰涂片中提取的DNA的方法。由于缺乏扩增,NAS-PCR控制假阴性结果的潜力已被证明在这些样品的研究中特别有用。研发的rpoB-PCR检测方法可用于临床实验室,以在耐多药结核病负担高的地区检测耐RIF的结核分枝杆菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号